Analysis of the focal relationship of level five leadership with school organizational excellence by Hosein Majooni, Siroos Ghanbari

“…To reach the success in the course of shocking transformations, our country's schools need level five leaders who, with the help of humble personality traits and exceptional charms along with a professional, organized and hard-working spirit, provide the necessary commitment and enthusiasm to achieve the highest level of school performance and excellence. …”
Get full text

Development of the destination branding model based on tourism industry nostalgia by parinaz masoumi, vahidreza mirabi, jalal HaghighatMonfared, Ahmad Vedadi

“…Host tourism culture (including indicators of respect for tourists and hospitality, respect for different ethnic groups and beliefs of tourists, the spirit of accepting tourists, compliance with individual and social norms and values, etc.) were selected as a category of intervening conditions to present a brand development model based on the role of nostalgia on the tourist's travel decision in the tourism industry. …”
Get full text

The effect of intellectual capital and strategic leadership on organizational citizenship behavior with the moderating role of employees' professional ethics by seyed reza mousavifard

“…Therefore, it can be said that due to the nature of strategic leadership, which has the role of formulating a vision in the organization by creating motivation and working spirit in its employees and tries to improve communication between employees, it can have an effect on organizational citizenship behavior. …”
Get full text

Should the Food and Drug Administration Limit Placebo-Controlled Trials? by Max Goodman, Connor Pedersen

“…Extreme care must be taken to avoid abuse of this option.[4] The FDA has largely ignored this and deemed placebo controls the gold standard, stating that “PCTs are necessary to control for placebo effect of investigational medicinal product.”[5] The FDA has even refused to approve drugs that are tested against established treatments instead of against placebos, notably atenolol.[6] By stretching the “methodological” exception and failing to define harm reasonably, the FDA does not meet the spirit behind Helsinki’s conditions for allowing PCTs. …”
Get full text